Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Enterprise Value (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Enterprise Value data on record, last reported at -$29.4 million in Q3 2025.

  • For Q3 2025, Enterprise Value fell 7.15% year-over-year to -$29.4 million; the TTM value through Sep 2025 reached -$29.4 million, down 7.15%, while the annual FY2024 figure was -$34.8 million, 21.84% up from the prior year.
  • Enterprise Value reached -$29.4 million in Q3 2025 per PLX's latest filing, up from -$33.4 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$20.8 million in Q3 2022 and bottomed at -$76.9 million in Q2 2021.
  • Average Enterprise Value over 5 years is -$40.0 million, with a median of -$34.8 million recorded in 2024.
  • Peak YoY movement for Enterprise Value: crashed 119.89% in 2021, then skyrocketed 62.86% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$39.0 million in 2021, then surged by 43.11% to -$22.2 million in 2022, then plummeted by 100.9% to -$44.6 million in 2023, then increased by 21.84% to -$34.8 million in 2024, then increased by 15.68% to -$29.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$29.4 million in Q3 2025, -$33.4 million in Q2 2025, and -$34.7 million in Q1 2025.